SCHEMBL31444461

SCHEMBL31444461

Fc1ccc(C2CCCCCN2)c(Cl)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR2A P28223 1/20 0.40
▸ HTR2C P28335 1/20 0.40
▸ SLC6A4 P31645 1/20 0.40
▸ HTR2B P41595 1/20 0.40
▸ MEN1 O00255 3/20 0.39
▸ KMT2A Q03164 3/20 0.39
▸ NPC1 O15118 2/20 0.38
▸ RAB9A P51151 2/20 0.38
▸ OPRL1 P41146 5/20 0.38
▸ CYP2D6 P10635 2/20 0.36
▸ CYP2C19 P33261 2/20 0.36
▸ POLB P06746 1/20 0.36
▸ CHRNB2 P17787 1/20 0.36
▸ CHRNA7 P36544 1/20 0.36
▸ CHRNA4 P43681 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ KCNH2 Q12809 1/20 0.36
▸ CYP1A2 P05177 1/20 0.36
▸ CYP2A6 P11509 1/20 0.36
▸ CYP2C9 P11712 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31444311 0.98 HTR2A (0.41) HTR2AHTR2CSLC6A4HTR2BMEN1
SCHEMBL25316221 0.94 MEN1 (0.44) HTR2AHTR2CSLC6A4HTR2BMEN1
SCHEMBL28519635 0.94 MEN1 (0.44) HTR2AHTR2CSLC6A4HTR2BMEN1
SCHEMBL24654623 0.88 OPRL1 (0.44) SLC6A4MEN1KMT2ANPC1RAB9A
SCHEMBL30423645 0.82 MEN1 (0.42) HTR2AHTR2CHTR2BMEN1KMT2A
SCHEMBL1765144 0.82 MEN1 (0.42) HTR2AHTR2CHTR2BMEN1KMT2A
SCHEMBL2239281 0.81 MEN1 (0.41) SLC6A4MEN1KMT2AOPRL1KCNH2
SCHEMBL2239285 0.81 MEN1 (0.41) SLC6A4MEN1KMT2AOPRL1KCNH2
SCHEMBL2707261 0.79 MEN1 (0.43) MEN1KMT2AOPRL1CYP2D6CYP2C19
Hydrochloric Acid SCHEMBL15017219 0.79 OPRL1 (0.40) HTR2AHTR2CSLC6A4MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025072451-A1 RAS-PI3K INHIBITORS FOR THE TREATMENT OF CANCER AND IMMUNOLOGICAL DISEASES VIVIDION THERAPEUTICS, INC. (US) 2025-04-03 — — WO disclosed
Send feedback